NovaBay Pharmaceuticals Issues a Reminder of Important Information Regarding the Pending Special Dividend and Upcoming 2025 Annual Meeting
September 18, 2025 16:30 ET | Source: NovaBay Pharmaceuticals Inc. EMERYVILLE, Calif.,…
89bio, Inc. Announces Agreement to be Acquired by Roche
September 18, 2025 01:02 ET | Source: 89bio, Inc. – 89bio stockholders…
Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH
89bio’s pegozafermin allows for a potentially best-in-disease treatment for moderate to severe…
Science Based Targets initiative (SBTi) validates EUROAPIs near-term climate targets
42% reduction in Scope 1 and 2 Greenhouse Gas emissions by 2030…
The Global Citizen Hub Announces Launch of European Scholarship Database for International Students
Austin, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The Global Citizen Hub…
C3.AI SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against C3.ai, Inc. – AI
NEW ORLEANS, Sept. 17, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder…
DOW SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Dow Inc. – DOW
NEW ORLEANS, Sept. 17, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder…
Arcutis To Present Multiple New ZORYVE (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress
New analysis of ZORYVE foam 0.3% demonstrates reduction in signs and symptoms…
ALK and GenSci partner to expand the AIT market in China
Inside Information GenSci is granted exclusive rights to ALK’s house dust mite…
Opterion Health AG submits Clinical Trial Application for First-in-Human Study of OPT101 in Patients with Advanced Chronic Kidney Disease
MUTTENZ, Switzerland, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Opterion Health AG, a…
